Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/LGT.0000000000000043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders.
Biomolecules
November 2024
Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy.
Neutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist's therapeutic armamentarium that are credited with potent anti-neutrophilic effects. Anti-neutrophilic drugs have established themselves as versatile agents in the treatment of a wide range of dermatological conditions.
View Article and Find Full Text PDFEffects of immune cells in mediating the relationship between inflammatory bowel disease and pyoderma gangrenosum: a two-sample, two-step mendelian randomization study.
Arch Dermatol Res
January 2025
Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Article Synopsis
- The study investigates the link between pyoderma gangrenosum (PG) and inflammatory bowel disease (IBD), highlighting that while the exact cause of their co-occurrence is unclear, there is evidence suggesting IBD increases the risk of PG.
- Researchers utilized genome-wide association study data to analyze the genetic relationship and potential mediating role of immune cells between the two conditions, employing various statistical techniques.
- The results indicated that IBD significantly raises the risk of PG, with specific types of IBD (ulcerative colitis and Crohn's disease) strongly correlating with this risk, and CD4 regulatory T cells playing a key mediating role in this interaction.
A case of treatment-resistant erosive pustular dermatosis of the scalp.
SAGE Open Med Case Rep
January 2025
Memorial University of Newfoundland, St. John's, NL, Canada.
Erosive pustular dermatosis is a rare and chronic inflammatory condition of the scalp which can be mistaken for cutaneous malignancy, precancerous lesions, dermatitis or pyoderma gangrenosum. The recurrent and resistant characteristics of erosive pustular dermatosis of the scalp pose a challenge to successful management and remission of the condition. The purpose of this case report is to provide management options and treatment recommendations for refractory cases of erosive pustular dermatosis of the scalp.
View Article and Find Full Text PDFAutoinflammatory Bone Diseases.
Balkan Med J
January 2025
Department of Pediatric Rheumatology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
Autoinflammatory bone diseases (AIBDs) constitute a recently identified subset of autoinflammatory diseases. These conditions are characterized by an exaggerated inflammatory response in the bones without any apparent etiology. Inflammatory bone lesions associated with AIBDs exhibit chronic inflammation, are typically culture-negative, and do not exhibit discernible microorganisms on histopathological examination.
View Article and Find Full Text PDFFeatures, Treatments, and Therapeutic Outcomes of Peristomal versus Non-Peristomal Pyoderma Gangrenosum in 45 Patients with Inflammatory Bowel Disease: A Single-Institution Study, 2002 through 2021.
Skinmed
January 2025
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA.
Pyoderma gangrenosum (PG) is the second most common skin manifestation reported in patients with inflammatory bowel disease (IBD). We performed a single-institution, retrospective study to summarize the clinical features and examine effective treatment regimens and outcomes of PG in IBD patients. We identified 45 patients who presented to our institute between January 1, 2002 and December 31, 2021 with the following criteria: (1) diagnosed with an active PG (ICD9: 686.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!